BioLine Rx (BioLine Rx) Total Assets : $63.93 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Total Assets?

BioLine Rx's Total Assets for the quarter that ended in Dec. 2023 was $63.93 Mil.

During the past 12 months, BioLine Rx's average Total Assets Growth Rate was -17.30% per year. During the past 3 years, the average Total Assets Growth Rate was -5.40% per year. During the past 5 years, the average Total Assets Growth Rate was -3.40% per year. During the past 10 years, the average Total Assets Growth Rate was 36.30% per year.

During the past 13 years, BioLine Rx's highest 3-Year average Total Assets Growth Rate was 98.90%. The lowest was -23.10%. And the median was 15.00%.

Total Assets is connected with ROA %. BioLine Rx's annualized ROA % for the quarter that ended in Dec. 2023 was -95.11%. Total Assets is also linked to Revenue through Asset Turnover. BioLine Rx's Asset Turnover for the quarter that ended in Dec. 2023 was 0.08.

BioLine Rx Total Assets Historical Data

The historical data trend for BioLine Rx's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Total Assets Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

53.57

47.29

81.39

76.38

63.93

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															76.38	68.65	58.94	52.86	63.93

BioLine Rx Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BioLine Rx's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	13.223	+	50.702
	=	63.93

BioLine Rx's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	13.223	+	50.702
	=	63.93

BioLine Rx (NAS:BLRX) Total Assets Explanation

Total Assets is connected with ROA %.

BioLine Rx's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-55.536	/	( (52.855	+	63.925)	/ 2 )
	=	-55.536	/	58.39
	=	-95.11 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BioLine Rx's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	4.8	/	( (52.855	+	63.925)	/ 2 )
=	4.8	/	58.39
=	0.08

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BioLine Rx Total Assets Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.